Cyp3A4 *1G多态性与饮酒有关:在中国进行了一项为期5年的回顾性单一以人群为中心的基于人口的研究
Xiaoqing Jia1, Xiaoting Zhang2, Tao Zhou2
1Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan, Shandong, China.
PloS one
|December 20, 2023
概括
CYP3A4*1G基因突变与更高的酒精滥用风险有关,并与心血管和恶性疾病相关. 然而,它没有显著影响过度饮酒者肝脏或脂质水平.
科学领域:
- 药物基因组学 药物基因组学
- 流行病学 流行病学
- 临床遗传学 临床遗传学
背景情况:
- 研究了细胞染色体P450 (CYP) 3A4基因型的患病率.
- 研究了CYP3A4基因型与酒精消费模式之间的关联.
研究的目的:
- 为了确定CYP3A4*1G基因型的流行病学特征.
- 评估CYP3A4*1G基因型与饮酒习惯之间的关系.
- 评估CYP3A4*1G突变对酒精消费者的肝功能,脂质水平和其他疾病的影响.
主要方法:
- 对630名接受CYP3A4*1G基因检测的患者进行了回顾性研究.
- 对流行病学,病因学和临床数据的分析,包括肝功能和血清脂质.
- 两变逻辑回归用于分析饮酒与CYP3A4*1G基因型之间的关联.
主要成果:
- 与野生型 (GG) 相比,CYP3A4*1G突变 (GA+AA) 显示,滥用酒精的几率增加了2.56倍.
- 在滥用酒精者中,CYP3A4*1G突变型和野生型组之间没有观察到肝损伤或血清脂水平的显著差异.
- CYP3A4*1G突变与心血管和恶性疾病的几率增加有关.
结论:
- 饮酒与CYP3A4*1G基因突变之间存在显著的关联.
- 在滥用酒精的个体中,CYP3A4*1G突变似乎没有影响肝损伤或脂质失调症.
- CYP3A4*1G突变与心血管和恶性疾病的风险增加有关.
相关概念视频
01:12Analysis of Population Pharmacokinetic Data
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:16Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...